Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.12.18
Views: 142

Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA

Dr Shannon Maude speaks to ecancer at ASH 2018 about inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy.

She explains that the study investigated whether adding another immunotherapy agent to the CAR T-cell therapy regimen to prevent this effect could extend treatment response and improve outcomes for children with relapsed B-ALL.

Dr Maude reveals that in half of the patients who lost the CAR-T cells early on the combination of the reinfusion of CAR-T cells with PD-1 blockade extended the persistence.

Watch her press conference here.

Read the article here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content. 
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation